This project addresses the urgent need for effective antiviral treatments against SARS-CoV-2, the virus causing COVID-19. The virus's rapid spread and high mortality rate, along with the limited effectiveness of existing treatments, highlight the necessity for new therapeutic strategies. The project focuses on the viral spike (S) protein, crucial for the virus's entry and infection of human cells. The spike protein is cleaved by proprotein convertases (PCs), a step essential for viral infectivity. Inhibiting this cleavage could significantly reduce the virus's ability to infect and spread. Since the convertase Furin also plays a critical role in other severe diseases, including cancer and deadly infections, finding novel inhibitors is highly motivated.
This research is vital for society, given the global health and economic crises caused by COVID-19. Developing effective antiviral drugs is crucial for managing the current pandemic and preparing for future viral outbreaks. By targeting PCs and developing innovative high-throughput screening (HTS) platforms, the project aims to identify potent inhibitors for new antiviral drugs. These drugs could be essential tools in the global fight against COVID-19 and other viral diseases, ultimately saving lives and helping restore normalcy to society.
Objectives
The project aimed to thoroughly understand the interaction between the SARS-CoV-2 spike protein and proprotein convertases, particularly Furin. It sought to develop two high-throughput screening platforms: an in vitro platform using synthetic substrates and soluble enzymes, and a cell-based platform using luciferase and apoptosis sensors. Additionally, the project emphasized sustainability in research by minimizing the use of non-renewable resources, recycling laboratory materials, and promoting eco-friendly practices.
Achievements
The project successfully advanced the understanding of how the SARS-CoV-2 spike protein interacts with proprotein convertases. It developed innovative platforms for screening potential inhibitors, leading to the identification of several promising compounds that could serve as leads for new antiviral drugs. The research provided detailed insights into the cleavage of the spike protein by Furin, a process essential for the virus's ability to infect human cells. Two high-throughput screening platforms were created: an in vitro platform using synthetic substrates and soluble enzymes, and a novel cell-based platform using luciferase and apoptosis sensors.
The project also identified several small molecules that effectively inhibit Furin activity, showing promise in reducing the infectivity of SARS-CoV-2. Sustainable research practices were incorporated throughout the project, including minimizing the use of non-renewable resources, recycling materials, and promoting eco-friendly practices.
In summary, this project addressed a critical need in the fight against COVID-19 by targeting a novel aspect of the virus's life cycle, with significant implications for public health and future pandemic preparedness. It not only contributed to the scientific understanding of SARS-CoV-2 but also provided practical tools and potential therapeutic leads to combat the virus and other PC-related pathologies, such as cancer and other viral infections.
